Multiple Sclerosis Journal · 2021 · 16 citations · 7 references
MedicineImmunologyNeurologyGlial BiologyNeuroimmunologyNeuropathologyDemyelinating DiseasesDemyelinating DisordersGlial PathologyNervous System PathologyNeuroinflammationReactive GliosisMog Antibody DiseaseMog Antibody-associated DiseaseMyelin Oligodendrocyte Glycoprotein Antibody-associated DiseaseMyelin-associated GlycoproteinNeuroaxonal DamageNeuroaxonal Injury BiomarkersNeuroinflammatory BiomarkersNeuroinflammatory Disease Biomarkers
To evaluate the occurrence of attack-independent neuroaxonal and astrocytic damage in myelin oligodendrocyte glycoprotein antibody-associated disease (MOGAD), serum neurofilament light chain (sNfL) and serum glial fibrillary acidic protein (sGFAP) levels were longitudinally measured in 102 sera using a single-molecule array assay. Sera from 15 adults with relapsing MOGAD with available longitudinal samples for the median 24-month follow-up and 26 age-/sex-matched healthy controls were analyzed. sNfL levels were significantly elevated in all clinical attacks, where the levels decreased below or close to cut-off value within 6 months after attacks. sNfL levels were consistently low during inter-attack periods. In contrast, sGFAP levels did not increase in most clinical attacks and remained low during follow-up. Significant neuroaxonal damage was observed at clinical attacks, while attack-independent neuroaxonal and astrocytic injury was absent in MOGAD.
7
Serum Glial Fibrillary Acidic Protein: A Neuromyelitis Optica Spectrum Disorder Biomarker
Orhan Aktaş, Michael Smith, William A. Rees et al. · Annals of Neurology · 2021 · 136 citations · Full text
Xuechun Chang, Wenjuan Huang, Liang Wang et al. · Frontiers in Immunology · 2021 · 75 citations · Full text